This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Livmarli (maralixibat)
General Description:
Livmarli (maralixibat) is an oral solution used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) who are 1 year of age and older.
Maralixibat is a selective ileal bile acid transporter (IBAT) inhibitor that works by blocking the reabsorption of bile acids in the small intestine. This reduces bile acid buildup in the liver and bloodstream, alleviating the severe itching (pruritus) commonly associated with cholestatic liver diseases such as ALGS.
Disease Indications:
Alagille Syndrome (ALGS)
Manufacturer:
Mirum Pharmaceuticals
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• One bottle of 9.5 mg/30 mL oral solution
Shipping:
Room Temperature Shipping
Livmarli is a stable oral formulation that does not require refrigeration. It is shipped under standard room temperature conditions (15°C to 25°C) using certified medical couriers to ensure consistent quality and efficacy throughout transit.
This standard shipping process is more economical than cold chain delivery while still maintaining the product’s stability and therapeutic effectiveness.
How to Access Livmarli (maralixibat) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Livmarli (maralixibat) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
